ProQR Therapeutics (NASDAQ:PRQR) was upgraded by stock analysts at ValuEngine from a “hold” rating to a “buy” rating in a note issued to investors on Thursday.
Other research analysts have also issued reports about the stock. Zacks Investment Research lowered shares of ProQR Therapeutics from a “buy” rating to a “hold” rating in a research note on Saturday, April 21st. Chardan Capital assumed coverage on shares of ProQR Therapeutics in a research note on Thursday, April 5th. They set a “buy” rating and a $4.50 price objective for the company. Six equities research analysts have rated the stock with a buy rating, ProQR Therapeutics presently has a consensus rating of “Buy” and an average price target of $16.10.
ProQR Therapeutics opened at $5.05 on Thursday, MarketBeat reports. ProQR Therapeutics has a fifty-two week low of $2.75 and a fifty-two week high of $6.90. The company has a debt-to-equity ratio of 0.19, a current ratio of 5.64 and a quick ratio of 5.64.
ProQR Therapeutics (NASDAQ:PRQR) last posted its quarterly earnings data on Wednesday, May 16th. The biopharmaceutical company reported ($0.42) EPS for the quarter, topping the consensus estimate of ($0.48) by $0.06. research analysts anticipate that ProQR Therapeutics will post -1.53 EPS for the current fiscal year.
Hedge funds and other institutional investors have recently bought and sold shares of the business. Wells Fargo & Company MN boosted its stake in ProQR Therapeutics by 212.6% during the third quarter. Wells Fargo & Company MN now owns 43,226 shares of the biopharmaceutical company’s stock worth $210,000 after buying an additional 29,400 shares during the period. Artal Group S.A. boosted its stake in ProQR Therapeutics by 26.7% during the fourth quarter. Artal Group S.A. now owns 1,900,000 shares of the biopharmaceutical company’s stock worth $6,128,000 after buying an additional 400,000 shares during the period. Jennison Associates LLC boosted its stake in ProQR Therapeutics by 7.3% during the fourth quarter. Jennison Associates LLC now owns 2,635,552 shares of the biopharmaceutical company’s stock worth $8,500,000 after buying an additional 178,192 shares during the period. Sabby Management LLC purchased a new position in ProQR Therapeutics during the fourth quarter worth $1,120,000. Finally, JPMorgan Chase & Co. boosted its stake in ProQR Therapeutics by 519.0% during the first quarter. JPMorgan Chase & Co. now owns 33,425 shares of the biopharmaceutical company’s stock worth $103,000 after buying an additional 28,025 shares during the period. 37.26% of the stock is owned by institutional investors.
About ProQR Therapeutics
ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. Its lead product candidate includes QR-010, a RNA-based oligonucleotide used for the treatment of cystic fibrosis; QR-110, an oligonucleotide that is designed to treat Leber's congenital amaurosis; and QR-313, a single-stranded oligonucleotide used for the treatment of epidermolysis bullosa.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for ProQR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProQR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.